



Program Committee Co-Chairpersons

Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY, USA
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

This historic event highlighted the latest and most exciting discoveries in major areas of cancer research, and provided a unique opportunity for investigators from all over the world to meet, network, and forge new scientific interactions. The meeting served as a dynamic platform for the advancement of cancer science and medicine, and for the establishment of new collaborations on an international scale. The multidisciplinary program covered the entire cancer research spectrum – from basic, to translational, to clinical – drawing on the latest findings presented at the 105th Annual Meeting of the AACR held in San Diego, April 5-9, 2014. The conference featured talks from an outstanding roster of international speakers and local experts.

This conference was the first event organized by the AACR International Office in Shanghai. In April 2014, the AACR was pleased to announce the opening of this first satellite office outside the U.S., which will help better serve the needs of scientists and clinicians in China, and across the Asia Pacific region. The AACR has established AACR International to stimulate innovative global collaborations by fostering the exchange of information on the latest research developments between laboratory and clinical researchers around the world.

Supporters

DIAMOND SUPPORTER



PLATINUM SUPPORTER



AWARD SUPPORTER



The AACR would like to thank the following organizations for their generous support of this conference.

Chinese Anti-Cancer Association

Chinese Society of Clinical Oncology

Cancer Foundation of China

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Chinese Society of Oncology

US Chinese Anti-Cancer Association

Chinese American Hematologists and Oncologists Network

NEW HORIZONS IN CANCER RESEARCH



Conference Program

Thursday, October 9

14:00-16:00 **Workshop: Community Standards for Next-Gen Sequencing in Oncology: The Actionable Genome Consortium**

16:30-19:00 **Opening Ceremony**

Welcome and Opening Remarks

Keynote Presentations

Synergistic target therapy against human cancer in an era of “health for all”: Lesson learnt from acute promyelocytic leukemia and beyond

Zhu Chen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Targeting KRAS in human cancer

Frank McCormick, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

19:00-21:00 **Opening Reception**

Friday, October 10

8:30-10:30 **Plenary Session 1: Metabolism and Cancer**

Co-Chairpersons: Hongyang Wang, Shanghai Cancer Institute, Shanghai, China; and Frank McCormick, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Large scale approaches to study cancer metabolism

David M. Sabatini, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

The LKB1-AMPK tumor suppressor pathway: Metabolic reprogramming and therapeutic targeting

Reuben J. Shaw, Salk Institute, La Jolla, CA, USA

Metabolic adaptation in cancer cells

Tak W. Mak, Campbell Family Institute for Cancer Research, Toronto, ON, Canada

Acetylation control of metabolic enzymes in cancer

Qunying Lei, Fudan University, Shanghai, China

10:30-11:00 **Tea Break**

11:00-12:30 Plenary Session 2: Epidemiology and Cancer Prevention
Co-Chairpersons: Yilong Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Cory Abate-Shen, Columbia University Irving Comp. Cancer Center, New York, NY

Using cross-species analysis of genome-wide regulatory networks to identify key drivers of prostate cancer malignancy

Cory Abate-Shen, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA

Consortium efforts to discover and characterize ovarian cancer risk variants

Thomas A. Sellers, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Profiling the molecular “field of injury” in airway epithelium for the early detection and prevention of lung cancer

Avrum E. Spira, Boston University, Boston, MA, USA

12:30-15:00 Lunch Break and Poster Session A

15:00-17:00 Plenary Session 3: Molecular Mechanisms of Tumorigenesis

Co-Chairpersons: Hong Wu, Peking University, Beijing, China; and Scott Lowe, Memorial Sloan Kettering Cancer Center, New York, NY, USA

PTEN and PTENa in tumor suppression and metabolism

Yuxin Yin, Peking University Health Science Center, Beijing, China

Mutant p53 activities in tumorigenesis

Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Signaling protein signature predicts cancer clinical outcome

Xuemin Zhang, National Center of Biomedical Analysis, Beijing, China

Where lies the heterogeneity in GBM?

Luis F. Parada, University of Texas Southwestern Medical Center, Dallas, TX, USA

17:00-17:30 Tea Break

17:30-19:30 Plenary Session 4: Immunology/Immunotherapy

Co-Chairpersons: Wenru Song, AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA; and Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD

Vaccine-induced immunity against cancer genes to prevent and treat pancreatic cancer

Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD, USA

Cancer immunoediting: Applying mechanistic insights to personalized cancer immunotherapy

Robert D. Schreiber, Washington University, St. Louis, MO, USA

Response and resistance to PD-1 blockade therapy

Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Immune system as a double-edged sword in cancer

Chen Dong, Tshingua University, Beijing, China

Saturday, October 11

8:30-10:30 Plenary Session 5: Cancer Models

Co-Chairpersons: Xiaodong Wang, National Institute of Biological Sciences, Beijing, China; and Douglas R. Green, St. Jude Children's Research Hospital, Memphis, TN

Probing survival at the single cell level

Douglas R. Green, St. Jude Children's Research Hospital, Memphis, TN, USA

Tumor suppressor and tumor maintenance genes

Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Polycomb group proteins in intestinal tumorigenesis

Rongwen Xi, National Institute of Biological Sciences, Beijing, China

Lgr5 stem cells in self-renewal and cancer

Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

10:30-11:00 Tea Break

11:00-12:30 Plenary Session 6: Novel Anticancer Therapies – Clinical Trials

Co-Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; and Jianmin Xu, Zhongshan Hospital, Fudan University, Shanghai, China

New targets, new drugs, new trial designs in the genomics era

Lillian L. Siu, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Novel therapeutic approaches in the treatment of lung cancer

Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong, China

Development of a new class of STAT3 inhibitors for cancer therapy

Boon-Cher Goh, National University Hospital of Singapore, Singapore

12:30-15:00 Lunch Break and Poster Session B

15:00-16:30 Plenary Session 7: Novel Anticancer Therapies – Drug Resistance

Co-Chairpersons: Mao Mao, WuXi AppTec, Shanghai, China; and William N. Hait, Janssen Research and Development, LLC, Raritan, NJ, USA

Presurgical trials in breast cancer: Role in clinical development and discovery of mechanisms of drug resistance

Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Developing combination therapies to overcome resistance to targeted therapies

Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA, USA

New insights into castration-resistant prostate cancer

Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

16:30-17:00 **Tea Break**

17:00-19:00 **Plenary Session 8: Cancer Genetics and Genomics**

Co-Chairpersons: Qimin Zhan, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China; and Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Sequencing and functional genomic approaches to cancer discovery

Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Roles for transcriptional super-enhancers in cell identity and cancer

Richard A. Young, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Enhancer malfunction in cancer

Ali Shilatifard, Northwestern University, Evanston, IL, USA

Single cell characterization of circulating tumor cells from lung cancer patients

Fan Bai, Peking University, Beijing, China

20:00-21:00 **Professional Advancement Session 1 (concurrent) – Networking Roundtables**

20:00-21:00 **Professional Advancement Session 2 (concurrent) – Forum: “Getting Your Research Published in AACR’s Journals”**

Chairperson: Cory Abate-Shen, Columbia University, Herbert-Irving Comprehensive Cancer Center, New York, NY, USA

Sunday, October 12

8:30-10:30 **Plenary Session 9: Drug Discovery and Development**

Chairperson: Yigong Shi, Tsinghua University, Beijing, China

Identification of a new druggable pocket on K-Ras

Kevan Shokat, University of California, San Francisco, San Francisco, CA, USA

Clinical translation of bromodomain inhibition

James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA

Identification of new drug targets via functional screening of the whole-genome CRISPR/Cas knockout library

Wensheng Wei, Peking University, Beijing, China

From discovery to drug: An industry perspective

William N. Hait, Janssen Research and Development, LLC, Raritan, NJ, USA

10:30-11:30 **Closing Remarks and Departure**